the prospective trial to evaluate the efficancy of individial treatment for advanced NSCLC patients with wild-type of the tyrosine kinase domain of epidermal growth factor receptor (EGFR)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-10001620

Enrollment

Unknown

Registered

2010-08-04

Start date

2010-06-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Study group:Individial treatment according to RRM1, TS and so on

Controll group:Vinorelbine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >70 Years old; 2. histologically confirmed stage IIIb or IV non-small cell lung cancer; 3. initial treatment; 4. life expectancy of at least 3 months; 5. ECOG score <=2; 6. at least one target tumor lesion can be measured; 7. significant organ function well.

Exclusion criteria

Exclusion criteria: 1. no enough tumor tissue to detect EGFR; 2. symptomatic or uncontrolled brain metastasis; 3. no fit for the trial judged by investigator.

Design outcomes

Primary

Measure	Time frame
PFs;	—

Secondary

Measure	Time frame
DCR;OS;ORR;	—

Countries

China

Contacts

Public ContactHuang Cheng

cheng671@sina.com+86 13905010379

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026